Altogether our data indicate that MM patients may benefit from the combination of antibodies targeting PD-1/PD-L1 and CD38, which both activate the immune system against MM cells, but through different mechanisms of action. This evidence concerns the gene PDCD1 and Miyoshi myopathy.